Diabetische Nephropathie – Update 2012 - Was ist Nephrologie?

leitlinien für die praxis
21. Bakris GL, et al. Renal outcomes with different fixed-dose
combination therapies in patients with hypertension at
high risk for cardiovascular events (ACCOMPLISH): a prespecified
secondary analysis of a randomised controlled
trial. Lancet. 2010;375(9721):1173–81.
22. Mann JFE, et al. Renal outcomes with telmisartan, ramipril,
or both, in people at high vascular risk (the ONTAR-
GET study): a multicentre, randomised, double-blind,
controlled trial. Lancet. 2008;372(9638):547–53.
23. Redon J, et al. Safety and efficacy of low blood pressures
among patients with diabetes: subgroup analyses from the
ONTARGET (ONgoing Telmisartan Alone and in combination
with Ramipril Global Endpoint Trial). J Am Coll Cardiol.
2012;59(1):74–83.
24. Watschinger B. Stellungnahme des Vorstands der ÖGH zur
Doppelblockade des RAS. J Hypertonie. 2012;16(1):28.
25. Joannidis M, Schmid M, Wiedermann CJ. Prevention of
contrast media-induced nephropathy by isotonic sodium
bicarbonate: a meta-analysis. Wien Klin Wochenschr.
2008;120(23–24):742–8.
26. Kiski D, et al. Impact of renin-angiotensin-aldosterone
blockade by angiotensin-converting enzyme inhibitors
or AT-1 blockers on frequency of contrast medium-induced
nephropathy: a post-hoc analysis from the Dialysis-versus-Diuresis
(DVD) trial. Nephrol Dial Transplant.
2010;25(3):759–64.
27. KDOQI. Clinical practice guidelines and clinical practice
recommendations for diabetes and chronic kidney disease.
Am J Kidney Dis. 2007;49(2):12–154.
28. The Diabetes Control and Complications Trial Research
Group. The effect of intensive treatment of diabetes on the
development and progression of long-term complications
in insulin-dependent diabetes mellitus. N Engl J Med.
1993;329(14):977–86.
29. UKPDS. Intensive blood-glucose control with sulphonylureas
or insulin compared with conventional treatment
and risk of complications in patients with type 2 diabetes
(UKPDS 33). UK Prospective Diabetes Study (UKPDS)
Group. Lancet. 1998;352(9131):837–53.
30. Lewis EJ, et al. The effect of angiotensin-converting-enzyme
inhibition on diabetic nephropathy. The collaborative
study group. N Engl J Med. 1993;329(20):1456–62.
31. Brenner BM, et al. Effects of losartan on renal and cardiovascular
outcomes in patients with type 2 diabetes and
nephropathy. N Engl J Med. 2001;345(12):861–9.
32. Parving HH, et al. The effect of irbesartan on the development
of diabetic nephropathy in patients with type 2 diabetes.
N Engl J Med. 2001;345(12):870–8.
1 3
Diabetische Nephropathie – Update 2012 49